Press Releases + New

Date	Title and Summary	View
Toggle SummaryFeb 13, 2014	Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference Noteworthy Panel of Oncology Experts Focuses on Immunotherapy as an Important Cancer Treatment Modality	View HTML Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference 18.8 KB
Toggle SummaryFeb 05, 2014	Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference	View HTML Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference 13.1 KB
Toggle SummaryFeb 03, 2014	Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma	View HTML Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma 18.3 KB
Toggle SummaryJan 27, 2014	Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration	View HTML Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration 20 KB
Toggle SummaryJan 23, 2014	Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase	View HTML Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase 14.6 KB
Toggle SummaryJan 21, 2014	Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis	View HTML Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis 69.4 KB
Toggle SummaryJan 15, 2014	Galectin Therapeutics Supports Investigational New Drug (IND) Application for Its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma IND Submitted by Providence Portland Medical Center, a Leading Cancer Immunotherapy Research Institute	View HTML Galectin Therapeutics Supports Investigational New Drug (IND) Application for Its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma 19.4 KB
Toggle SummaryJan 13, 2014	Galectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis	View HTML Galectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 19 KB
Toggle SummaryJan 10, 2014	Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million	View HTML Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million 14.1 KB
Toggle SummaryJan 08, 2014	Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity	View HTML Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity 16.8 KB